Clinical trial
A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study)
NCT01234766 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study)
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2010
- Completion date
- April 1, 2021
- Enrollment
- 39 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.